Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions

Abstract

The PROGENSA PCA3 assay can aid in guiding biopsy decisions. It is superior to total prostate specific antigen, prostate specific antigen density and %free prostate specific antigen in predicting initial biopsy outcome, and may be indicative of prostate cancer aggressiveness.